Exact Sciences announced strong financial results for the second quarter of 2024, reporting $699 million in revenue, a 12% increase from the previous year. The company screened over 1 million people with Cologuard® and advanced its product pipeline, including new AI-driven diagnostics. Exact Sciences raised its adjusted EBITDA guidance for the full year and highlighted significant achievements in cancer screening and diagnostics. The company’s Precision Oncology portfolio continues to provide critical genomic insights for cancer treatment.
Keep Reading
Add A Comment